BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
Chinese Patent Office
Citi
Deloitte
US Department of Justice
Cipla
Accenture
Farmers Insurance
Moodys
Johnson and Johnson

Generated: January 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,514,520

« Back to Dashboard

Which drugs does patent 6,514,520 protect, and when does it expire?

Patent 6,514,520 protects CLARINEX and is included in one NDA.

Protection for CLARINEX has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-one patent family members in twenty-eight countries.
Summary for Patent: 6,514,520
Title: Stabilized antihistamine syrup
Abstract:An antihistaminic syrup is stabilized against degradation of the active ingredient, by the addition of and about 0.05 to about 5 mg/mL of an aminopolycarboxylic acid such as a salt of ethylenediaminetetraacetic acid.
Inventor(s): Munayyer; Farah J. (West Caldwell, NJ), Guazzo; Frank (Bridgewater, NJ), Stupak; Elliot I. (West Caldwell, NJ), Chaudry; Imtiaz A. (North Caldwell, NJ), Sequeira; Joel A. (Edison, NJ)
Assignee: Schering Corporation (Kenilworth, NJ)
Application Number:09/899,764
Patent Claim Types:
see list of patent claims
Formulation; Compound;

Drugs Protected by US Patent 6,514,520

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Merck Sharp Dohme CLARINEX desloratadine SOLUTION;ORAL 021300-001 Sep 1, 2004 AA RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,514,520

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,132,758 Stabilized antihistamine syrup ➤ Subscribe
6,939,550 Stabilized antihistamine syrup ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,514,520

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Yugoslavia 23599 ➤ Subscribe
Portugal 1082117 ➤ Subscribe
Peru 05652000 ➤ Subscribe
Panama 8474201 ➤ Subscribe
New Zealand 508037 ➤ Subscribe
Norway 329124 ➤ Subscribe
Norway 20006079 ➤ Subscribe
Netherlands 1012191 ➤ Subscribe
Malaysia 123325 ➤ Subscribe
Japan 2005015485 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Colorcon
US Department of Justice
AstraZeneca
Queensland Health
Merck
UBS
Moodys
Harvard Business School
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot